Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Payables (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Payables data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Payables fell 58.36% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, down 58.36%, while the annual FY2024 figure was $3.3 million, 47.46% down from the prior year.
  • Payables reached $2.7 million in Q3 2025 per CAPR's latest filing, down from $4.8 million in the prior quarter.
  • Across five years, Payables topped out at $6.8 million in Q3 2023 and bottomed at $2.7 million in Q3 2025.
  • Average Payables over 5 years is $4.6 million, with a median of $4.8 million recorded in 2025.
  • Peak YoY movement for Payables: surged 189.44% in 2021, then tumbled 58.36% in 2025.
  • A 5-year view of Payables shows it stood at $3.1 million in 2021, then surged by 55.14% to $4.8 million in 2022, then grew by 29.28% to $6.3 million in 2023, then plummeted by 47.46% to $3.3 million in 2024, then decreased by 17.18% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $2.7 million in Q3 2025, $4.8 million in Q2 2025, and $5.3 million in Q1 2025.